Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cabotegravir injection - ViiV Healthcare

Drug Profile

Cabotegravir injection - ViiV Healthcare

Alternative Names: 1265744; 744 LA Injection; CAB LA - ViiV Healthcare; Cabotegravir long acting; Cabotegravir sodium; GSK-1265744; GSK-1265744A; GSK-1265744B; GSK-744; GSK-744-LA; GSK1265744 LAP; S-265744; S-265744B; S/GSK-1265744; S/GSK1265744 LAP

Latest Information Update: 26 Jul 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Shionogi - GlaxoSmithKline (JV)
  • Developer Gilead Sciences; National Institute of Allergy and Infectious Diseases; ViiV Healthcare
  • Class Amides; Antiretrovirals; Fluorobenzenes; Oxazoles; Pyrazines; Pyridones; Small molecules
  • Mechanism of Action HIV integrase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration HIV infections

Most Recent Events

  • 22 Jul 2021 Efficacy data from a phase II HPTN 084 trial in HIV-1 infection released by ViiV Healthcare
  • 22 Jun 2021 Viiv Healthcare in-licenses ENHANZE® drug delivery technology, recombinant human hyaluronidase PH20 enzyme (rHuPH20) from Halozyme Therapeutics
  • 28 May 2021 No recent reports of development identified for phase-I development in HIV-infections(In volunteers) in China (IM, Controlled release)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top